Bayer, Boehringer Ingelheim and Bristol-Myers Squibb side by side
Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.
At a glance
Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.
Pipeline by phase
Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.
| Furthest phase | Bayer | Boehringer Ingelheim | Bristol-Myers Squibb |
|---|---|---|---|
| Phase 1 | Bayer: 4 of its 21 programs at phase 1 | Boehringer Ingelheim: 18 of its 45 programs at phase 1
and 13 more — sign in to see them all | Bristol-Myers Squibb: 17 of its 57 programs at phase 1
and 12 more — sign in to see them all |
| Phase 2 | Bayer: 8 of its 21 programs at phase 2
and 3 more — sign in to see them all | Boehringer Ingelheim: 15 of its 45 programs at phase 2
and 10 more — sign in to see them all | Bristol-Myers Squibb: 17 of its 57 programs at phase 2
and 12 more — sign in to see them all |
| Phase 3 | Bayer: 4 of its 21 programs at phase 3
| Boehringer Ingelheim: 9 of its 45 programs at phase 3
and 4 more — sign in to see them all | Bristol-Myers Squibb: 16 of its 57 programs at phase 3
and 11 more — sign in to see them all |
| Approved, new studies | Bayer: 5 of its 21 programs at approved, new studies
| Boehringer Ingelheim: 3 of its 45 programs at approved, new studies
| Bristol-Myers Squibb: 7 of its 57 programs at approved, new studies
and 2 more — sign in to see them all |
Readouts ahead
Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.
| Nov ’26 | Dec | Jan ’27 | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bayer10 readouts · 4 phase 3 | · | Bayer, Dec ’26: 1 program whose next study reaches primary completion
| Bayer, Jan ’27: 1 program whose next study reaches primary completion
| · | Bayer, Mar ’27: 1 program whose next study reaches primary completion
| Bayer, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bayer, May ’27: 2 programs whose next study reaches primary completion
| · | Bayer, Jul ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bayer, Aug ’27: 1 program whose next study reaches primary completion
| Bayer, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bayer, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3
|
| Boehringer Ingelheim20 readouts · 3 phase 3 | · | Boehringer Ingelheim, Dec ’26: 8 programs whose next study reaches primary completion, 1 in phase 3
and 3 more — sign in to see them all | · | Boehringer Ingelheim, Feb ’27: 1 program whose next study reaches primary completion
| Boehringer Ingelheim, Mar ’27: 4 programs whose next study reaches primary completion
| Boehringer Ingelheim, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| · | Boehringer Ingelheim, Jun ’27: 1 program whose next study reaches primary completion
| Boehringer Ingelheim, Jul ’27: 2 programs whose next study reaches primary completion
| Boehringer Ingelheim, Aug ’27: 2 programs whose next study reaches primary completion
| · | Boehringer Ingelheim, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3
|
| Bristol-Myers Squibb22 readouts · 7 phase 3 | Bristol-Myers Squibb, Nov ’26: 2 programs whose next study reaches primary completion, 2 in phase 3
| Bristol-Myers Squibb, Dec ’26: 7 programs whose next study reaches primary completion, 1 in phase 3
and 2 more — sign in to see them all | Bristol-Myers Squibb, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bristol-Myers Squibb, Feb ’27: 3 programs whose next study reaches primary completion, 1 in phase 3
| Bristol-Myers Squibb, Mar ’27: 1 program whose next study reaches primary completion
| · | Bristol-Myers Squibb, May ’27: 1 program whose next study reaches primary completion
| Bristol-Myers Squibb, Jun ’27: 3 programs whose next study reaches primary completion
| Bristol-Myers Squibb, Jul ’27: 1 program whose next study reaches primary completion
| Bristol-Myers Squibb, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bristol-Myers Squibb, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3
| Bristol-Myers Squibb, Oct ’27: 1 program whose next study reaches primary completion
|
Changed in the last 90 days
Since Aug 22, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.
Bayer
New programs 0
None
Reached a new phase 1
- WRN Inhibitor RO7589831phase 2 · Sep 2 · Colorectal Neoplasms, Hereditary Nonpolyposis
Study stopped 0
None
Primary completion later 2
- darolutamideapproved, new study · Apr 2027 → Dec 2027 (+8 mo) · moved Nov 5 · NCT05348876
- bemdaneprocelphase 3 · Mar 2027 → Oct 2028 (+19 mo) · moved Oct 30 · NCT06944522
Boehringer Ingelheim
New programs 3
- BI 4015092phase 1 · first study · Nov 3
- BI 3968621phase 1 · first study · Sep 25
- pumitamigphase 2 · first study · Sep 22 · Carcinoma, Non-Small-Cell Lung
Reached a new phase 1
- BI 3810477phase 2 · Nov 3 · Idiopathic Pulmonary Fibrosis
Study stopped 0
None
Primary completion later 7
- BI 3000202phase 1 · Dec 2026 → Dec 2029 (+36 mo) · moved Nov 13 · NCT06878365
- BI 3000202phase 1 · Oct 2026 → Feb 2027 (+5 mo) · moved Nov 12 · NCT07774325
- vsv-gp BI 1831169phase 1 · Dec 2027 → Jul 2028 (+7 mo) · moved Nov 10 · NCT05155332
- zongertinibphase 1 · Dec 2026 → Feb 2028 (+14 mo) · moved Oct 28 · NCT04886804
- survodutidephase 3 · Jun 2028 → Nov 2029 (+16 mo) · moved Oct 27 · NCT07855900
- BI 1815368phase 2 · Sep 2027 → Mar 2028 (+6 mo) · moved Oct 16 · NCT06962839
+1 more
- VSV-based Oncolytic Virus-expressing IL12/GSDME BI 3923948phase 1 · Feb 2028 → Jun 2031 (+39 mo) · moved Oct 13 · NCT07395258
Bristol-Myers Squibb
New programs 5
- BMS-986548phase 2 · first study · Nov 10
- BMS-986485phase 1 · first study · Oct 14
- BMS-986553phase 1 · first study · Oct 8 · Lupus Nephritis
- RYZ711phase 2 · first study · Oct 1 · Prostatic Neoplasms
- BMS-986527phase 1 · first study · Sep 22 · Carcinoma, Renal Cell
Reached a new phase 0
None
Study stopped 0
None
Primary completion later 0
None
Where they overlap
Conditions where at least two of them have programs: 33 in all, the first 12 here. A program counts in each condition its studies name most.
Same targetBetaPro · free during the beta
Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.
| Target | Bayer | Boehringer Ingelheim | Bristol-Myers Squibb |
|---|---|---|---|
| CD3E | – | obrixtamig, Anti-B7-H6/Anti-CD3 Bispecific Antibody BI 765049rule | elranatamabrule |
| PDCD1 | – | ezabenlimab | atigotatug, Nivolumabrule |
| AR | darolutamiderule | – | dezandrodegrule |
| CD274 | – | pumitamig | pumitamig |
| EGFR | sevabertinibrule | – | izalontamab brengitecan |
| ERBB2 | sevabertinibrule | zongertinibrule | – |
| GPC3 | Actinium Ac 225 GPC3-targeted Antibody Conjugate BAY 3547926rule | – | Actinium Ac 225 GPC3-targeted Peptide RYZ801 |
| KRAS | KRAS G12D Inhibitor KQB548rule | – | adagrasibrule |
| PRMT5 | PRMT5 Inhibitor BAY 3713372rule | – | navlimetostat |
| VEGFA | – | pumitamig | pumitamig |
What this can't show
- Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
- Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
- Readout dates are the sponsors’ estimates, not results.
- A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
- “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
- Programs a company names but has not registered are counted apart (Boehringer Ingelheim: 21, Bristol-Myers Squibb: 9).